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ABSTRACT
We have shown previously that mutations in the apico-basal cell polarity regulators cooperate with
oncogenic Ras (RasACT ) to promote tumorigenesis in Drosophila melanogaster and mammalian cells. To iden-
tify novel genes that cooperate with RasACT in tumorigenesis, we carried out a genome-wide screen for genes
that when overexpressed throughout the developing Drosophila eye enhance RasACT-driven hyperplasia.
RasACT-cooperating genes identified were Rac1 Rho1, RhoGEF2, pbl, rib, and east, which encode cell mor-
phology regulators. In a clonal setting, which reveals genes conferring a competitive advantage over wild-
type cells, only Rac1, an activated allele of Rho1 (Rho1ACT), RhoGEF2, and pbl cooperated with RasACT,
resulting in reduced differentiation and large invasive tumors. Expression of RhoGEF2 or Rac1 with RasACT
upregulated Jun kinase ( JNK) activity, and JNK upregulation was essential for cooperation. However, in the
whole-tissue system, upregulation of JNK alone was not sufficient for cooperation with RasACT, while in the
clonal setting, JNK upregulation was sufficient for RasACT-mediated tumorigenesis. JNK upregulation was
also sufficient to confer invasive growth of RasV12-expressing mammalian MCF10A breast epithelial cells.
Consistent with this, HER21 human breast cancers (where human epidermal growth factor 2 is overex-
pressed and Ras signaling upregulated) show a significant correlation with a signature representing JNK
pathway activation. Moreover, our genetic analysis in Drosophila revealed that Rho1 and Rac are important
for the cooperation of RhoGEF2 or Pbl overexpression and of mutants in polarity regulators, Dlg and aPKC,
with RasACT in the whole-tissue context. Collectively our analysis reveals the importance of the RhoGEF/
Rho-family/JNK pathway in cooperative tumorigenesis with RasACT.
CANCER is a multistep process, and transformationfrom a normal cell to an invasive/metastatic cancer
has been considered to involve in six steps: (1) activation
of mitogen-signaling pathways to allow growth factor
independence; (2) elimination of cell-cycle inhibitors,
(3) prevention of apoptosis, (4) promotion of invasion
and metastasis, (5) acquiring unlimited replicative abil-
ity (upregulation of Telomerase), and (6) activation of
angiogenesis (reviewed by Hanahan and Weinberg
2000). In addition, there is strong evidence that normal
cells surrounding tumor cells (tumor microenvironment)
can significantly affect the growth and development of
the tumor and that the tumor and stroma (surrounding
normal cells) evolve together in the development of the
tumor (reviewed by Bissell and Radisky 2001). The
vinegar fly, Drosophila melanogaster, presents an excellent
genetically amenable system with which to model the
first four of these cancer hallmarks, as well as the inter-
action of tumor cells with their microenvironment (re-
viewed by Brumby and Richardson 2005).
Genetic analyses in Drosophila have revealed many
genes that when deregulated induce or contribute to
tumorigenesis. Drosophila tumor suppressors have been
classed as hyperplastic (such as those of the Salvador/
Warts/Hippo, SWH, pathway), which result in increased
proliferation or survival but do not disrupt tissue struc-
ture or differentiation, or neoplastic (such as Dlg, Scrib,
and Lgl), which lead to loss of tissue structure, differ-
entiation defects, and failure to exit the cell cycle (re-
viewed by Brumby and Richardson 2005; Hariharan
and Bilder 2006). Dlg, Scrib, and Lgl act antagonisti-
cally to the apical polarity modules, the atypical protein
kinase C (aPKC), and Crumbs (Crb) complexes, to
regulate epithelial apico-basal cell polarity and limit
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proliferation (reviewed by Humbert et al. 2008). We
have recently shown that deregulation of Lgl, aPKC, or
Crb promotes tissue growth without affecting cell polarity
by deregulation of the SWH pathway (Grzeschik et al.
2010). However, homozygous mutant epithelial tissue
from scrib, lgl, or dlg mutant larvae that has lost apico-
basal cell polarity shows all four hallmarks of cancer
that can be modeled in the fly; the tissue continues to
proliferate, does not die, fails to differentiate, and is ca-
pable of invasive behavior (Gateff and Schneiderman
1969; Gateff 1978; Woodhouse et al. 1998; Bilder and
Perrimon 2000; Bilder et al. 2000).
By contrast, when scrib or lgl mutant tissue is gener-
ated in the context of wild-type tissue in the developing
Drosophila eye using clonal analysis, it exhibits only
some of the hallmarks of cancer. While both lgl and
scrib mutant clones are unable to cease proliferation,
showing increased expression of the key G1-S-phase
cell-cycle regulator cyclin E (Richardson et al. 1993,
1995; Knoblich et al. 1994) and ectopic cell cycles, they
are still capable of differentiation, thereby preventing
overgrowth (Brumby and Richardson 2003; Grzeschik
et al. 2007). In addition, scribmutant cells are eliminated
by Jun kinase ( JNK)-mediated cell death that is in-
duced by the surrounding wild-type tissue (Brumby and
Richardson 2003). However, when activated Ras or Notch
oncogenes are expressed in scribmutant clones, cell sur-
vival is dramatically increased and invasive/metastatic
behavior is observed (Brumby and Richardson 2003;
Pagliarini and Xu 2003). This includes the breakdown
of the basement membrane and invasion/migration of
mutant cells to distant sites. Thus scrib loss-of-function
shows many hallmarks of cancer and exhibits the ability
to cooperate with oncogenic Ras or Notch in tumor
progression.
The cooperation of scrib loss-of-function with RasACT
and activated Notch (Notchintra or NotchACT) in tumori-
genesis most likely depends on the loss of cell polarity,
as mutations in other apico-basal cell polarity regulators
of the Scrib, aPKC, or Crb complexes can also cooper-
ate with oncogenic Ras in tumorigenesis in Drosophila
eye epithelial tissues (Pagliarini and Xu 2003). Fur-
thermore, overexpression of Crb, which results in a loss
of apico-basal cell polarity, cooperates with RasACT in
tumorigenesis (Leong et al. 2009). One important fac-
tor that contributes to RasACT-mediated cooperative
tumorigenesis with scrib-, revealed by our and other
studies, is the JNK signaling pathway (Brumby and
Richardson 2003; Igaki et al. 2006; Uhlirova and
Bohmann 2006; Leong et al. 2009). Blocking JNK func-
tion in scrib- RasACT tumors reestablishes differentiation
and reduces the tumor’s invasive properties. Downregu-
lation of the E-cadherin–b-catenin complex in apico-
basal polarity mutants also contributes to tumorigene-
sis (Igaki et al. 2006). Whether JNK activation and
E-cadherin–b-catenin downregulation are the only events
downstream of apico-basal polarity mutants contribut-
ing to RasACT-cooperative tumorigenesis is unclear. We
envisioned that insight might be gained on the nature
of other critical functions that are affected by loss of cell
polarity for RasACT-cooperative tumorigenesis, by iden-
tifying other genes that cooperate with oncogenic Ras.
In this study, we present the results of a genetic screen
to identify genes that when overexpressed enhance a
RasACT-induced hyperplastic eye phenotype. We iden-
tified key regulators of the actin cytoskeleton and
cell morphology, including Rho1-family GTPases and
RhoGEFs as RasACT-cooperating proteins. We show that
JNK pathway activation underlies the cooperation of
these actin cytoskeletal regulators with RasACT. More-
over, we show that JNK and Ras signaling cooperate
to promote invasive growth in normal human mammary
epithelial cells and reveal by bioinformatics analysis
that JNK signaling correlates with upregulation of Ras
in human breast cancer. Our studies reveal a RhoGEF/
Rho-family/JNK pathway as an important factor in onco-
genic Ras mediated tumorigenesis.
MATERIALS AND METHODS
Fly stocks, conditions of culture, overexpression, and clonal
analysis: For the screening of GS lines, a recombinant of ey-
GAL4 and UAS-Ras85DV12 (ey.RasACT ) was generated. Poten-
tial interacting GS lines were retested against ey.RasACT and
also to ey-GAL4 to assess the effect of expression of the gene
alone on the adult eye. At least 50 progeny were analyzed for
each cross, and representative images are shown. All flies were
raised on a standard cornmeal agar food at 25.
Validating transgenes used were: UAS-rib (Deborah
Andrew), UAS-Rho1CFP2a (Greco et al. 2001), UAS-Rho1ACT
(Billuart et al. 2001), UAS-RhoGEF2 (Udo Hacker, Widmann
and Dahmann 2009), UAS-east (Wasser and Chia 2000), UAS-
pbl-GFP#3, and UAS-pbl-GFP#8 (Robert Saint, Somers and
Saint 2003), UAS-Rac1 (Luo et al. 1994).
The MARCM (mosaic analysis with repressible cell marker)
system (Lee and Luo 2001) with FRT82B, ey-FLP, and UAS-GFP
(ey-FLP1, UASmCD8-GFP;;Tub-GAL4 FRT82B Tub-GAL80; Lee
and Treisman 2001) was used to induce GFP positively
marked clones.
Other stocks used were: dlg-RNAi 4689 C2V (gift from B.
Dickson, Dietzl et al. 2007), validated for knockdown of Dlg
and specificity (Grzeschik et al. 2010), msn06946 (msn-lacZ)
(Mattila et al. 2005); UAS-P35 (Hay et al. 1994); UAS-bskK53R
(UAS-bskDN) (Weber et al. 2000), UAS-aPKCDN (Betschinger
et al. 2003); UAS-aPKCCAAX-DN (Sotillos et al. 2004); UAS-
Ras85DV12 (UAS-RasACT ) (Karim and Rubin 1998); UAS-
Rac1N17 (UAS-Rac1DN) (Luo et al. 1994); UAS-Rho1RNAi
#12734 [Vienna Drosophila Resource Center (VDRC), Dietzl
et al. 2007] and scrib1 (D. Bilder).
Immunocytochemistry for analysis of Drosophila tissues:
For analysis of third-instar larval eye-antenna discs, the discs
were dissected in PBS, fixed in 4% PFA, washed in PBT (0.1%
TritonX-100), and blocked in PBT 1 2% normal goat serum.
BrdU labeling for the detection of S phase cells was carried
out as previously described (Leong et al. 2009). Antibodies used
were mouse Elav (Developmental Studies Hybridoma Bank,
DSHB, 1:20), mouse b-galactosidase (Rockland, 1:500), andmouse
anti-BrdU (Becton-Dickinson, 1:50). Secondary antibodies were:
anti-mouse Alexa647 (Invitrogen; 1:400) or anti-mouse Alexa488
(Invitrogen; 1:400). F-actin was detected with phalloidin-
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tetramethylrhodamine isothiocyanate (Rhodamine; Sigma,
0.3 mm).
Matrigel invasion assay for mammalian MCF10A cells:
Parental MCF10A cell lines were retrovirally co-infected with
JNK1a1, MKK4, and MKK7 overexpression constructs and
H-RasV12cherry selected with puromycin, sorted for GFP/cherry
on a FACSVantage SE-DiVa flow cytometer (Becton Dickinson,
Franklin Lakes, NJ), and maintained as previously described
(Dow et al. 2008). MCF10A derivative cell lines stably express-
ing candidate genes were quantified for invasive phenotypes
in 3D organotypic cultures as previously described (Dow et al.
2008) using growth factor-reduced Matrigel (BD Biosciences,
Franklin Lakes, NJ) and the standard overlay method (Debnath
et al. 2003; Dow et al. 2008). After 7 days in culture, individual
acini were classified as “normal” acini, defined as those with
a contiguous acini boundary with no cellular extensions, or
“invasive,” defined as acini with disorganized boundary struc-
tures showing cellular protrusions or cellular spikes invading
into the surrounding matrix. Cell lines were plated in dup-
licate wells for each experiment and 100 acini were scored per
well.
Constructs and antibodies for mammalian cell analysis:
JNK1a1, MKK4, and MKK7 overexpression constructs were
PCR amplified from Addgene plasmids 13798 (pcDNA3-Flag-
JNK1a1), 14615 (pcDNA3-Flag-MKK4), and 14538 (pcDNA3-
Flag-MKK7a1) and inserted into pMSCVpuro (clontech, PT3303-5)
or MSCV-IRES-GFP. MSCV-cherry-IRES-H-RasV12 and MSCV
control vectors were already available (Dow et al. 2008).
The following primary antibodies were used for prob-
ing Western blots: a-tubulin (no. T5168; Sigma-Aldrich),
Mouse anti-MKK7 (no. 32-7000, Invitrogen), monoclonal
mouse Anti-Flag (F3165, Sigma), rabbit anti-SEK1/MKK4
(no. 9152, cell signaling), rabbit anti-Ras (cloneMC57, no.
05-775, Upstate). Peroxidase-labeled horse anti-mouse IgG
(S1018, vector laboratories, Burlingame, CA) and goat anti-
rabbit IgG (no. 170-6515, Bio-Rad laboratories, Hercules,
CA) secondary antibodies were used for LiCor Western
blotting.
Scanning electron microscopy and imaging: Fluorescent
labeled samples were mounted in 80% glycerol and analyzed
by Confocal microscopy (Bio-Rad MRC1000 or Olympus
FV1000) and images were processed using Confocal AssistantR
and Fluorview software and assembled using Adobe Photo-
shop CS2 and Adobe Illustrator CS2. Adult eyes were imaged
with a Scitec Infinity1 camera. Scanning electron micrographs
of adult eyes were carried out as previously described
(Richardson et al. 1995), except that the samples were gold
coated before imaging and were imaged on a Philips XL30
FEG field-emission scanning electron microscope, at 2 V, and
working distance 10 mm.
Breast Cancer Gene expression data sets: Breast cancer
data sets used are publicly available and were downloaded
from the authors’ websites (see supporting information, File
S1). We used normalized data (log2 intensity in single-channel
platforms or log2 ratio in dual-channel platforms) and probe
sets were mapped to Entrez-Gene IDs to merge data across the
various datasets. Breast cancer subtypes were defined using
a two-dimensional clustering model previously described on
the basis of two module scores, ESR1 and HER2, representing
ER and HER2 phenotypes, respectively. Gene sets represent-
ing JNK and RAS signaling were combined to compute a gene
signature score defined as the weighted linear combination
of the log2 expression values of the genes in the signature.
Kruskal–Wallis tests were used to determine differences in
expression between classes and Spearman’s Rho correlations
were used to assess correlations between the signatures. For
further information see File S1.
RESULTS
A screen for RasACT-cooperating genes in the develop-
ing Drosophila eye reveals cell morphology regulators:
To identify novel genes able to cooperate with acti-
vated Ras85D (RasACT), we first sought to generate a hy-
perplastic phenotype mediated by RasACT that could
be used in an F1 screen. Expression of RasACT via the
eyeless-GAL4 (ey-GAL4) driver in the developing eye has
been previously shown to result in hyperplasia during
larval development and generates an overgrown adult
eye phenotype (Karim and Rubin 1998). Therefore, we
generated a stock containing ey-GAL4 and UAS-RasACT
(ey.RasACT ), which resulted in overgrown adult eyes
that was more obvious in males than females (Figure
1, A and B, and Figure S1). At the larval stage, the
expression of RasACT led to enlarged eye discs with en-
larged ommatidia and greater spacing between omma-
tidial clusters (Figure S3 and Figure S4), consistent with
the documented role of RasACT in cell growth and pro-
liferation (Karim and Rubin 1998; Prober and Edgar
2000). To validate that the phenotype of ey.RasACT was
responsive to genes known to cooperate with RasACT in
tumorigenesis, we tested if knocking down the junc-
tional neoplastic tumor suppressors, dlg, scrib, or lgl,
by RNAi, could enhance the phenotype. Indeed, dlg
knockdown enhanced the ey.RasACT hyperplastic eye
phenotype at the adult stage and resulted in subtly
larger eye discs than RasACT alone, with greater spacing
between ommatidial clusters (Figure 1D, Figure S3, and
Figure S4), but had no obvious defects when expressed
alone (Figure 1C, see Figure S3, and Figure S4). lgl or
scrib knockdown had only mild effects on the ey.RasACT
phenotype (data not shown), perhaps due to a lower
level of knockdown achieved with these RNAi lines. To
determine whether the ey.RasACT adult eye phenotype
was sensitive to increased activity of polarity regulators,
we then tested whether overexpression of an activated
version of the apical cell polarity regulator aPKC
(aPKCDN), which alone does not affect the adult eye,
could enhance the ey.RasACT phenotype. Indeed
ey.RasACT aPKCDN adult females exhibited strongly en-
hanced hyperplastic eyes (Figure 1, E and F, and Fig-
ure S1), whereas no males eclosed (presumably
reflecting the stronger phenotype of RasACT expression
exhibited in males). Furthermore, overexpression of the
apical cell polarity regulator Crb, via the ey driver,
resulted in an ablated eye phenotype alone, but was pu-
pal lethal with RasACT (data not shown). Thus, these data
show that deregulation of polarity regulators can en-
hance the RasACT phenotype and validate the use of
the ey.RasACT adult eye phenotype as a system suitable
for screening for genes that when overexpressed can co-
operate with oncogenic Ras, to increase hyperplasia or
result in pupal lethality.
To identify novel genes that when overexpressed co-
operate with RasACT, we screened the GS line collection
Cooperation of RhoGEF/Rho-Family/JNK With Ras 107
of enhancer P lines (Toba et al. 1999; Aigaki et al.
2001). The map position of these lines in the genome,
as well as the tagged gene (the gene that is overex-
pressed by the line) has, in most cases, been determined
and a database established to enable ready access to this
information (http://gsdb.biol.metro-u.ac.jp/%7Edclust/).
This enhancer P transgenic set has been successfully
used in several screens to identify interacting genes
(Aigaki et al. 2001; Kanuka et al. 2005; Laviolette
et al. 2005; Zhang et al. 2006). To identify enhancers
of RasACT, we carried out an F1 screen, scoring for lines
that enhanced the mild hyperplastic phenotype of
ey.RasACT. Approximately 5000 GS lines were screened
and lines that scored as moderate or strong enhancers
were retested against ey.RasACT. Confirmed interacting
GS lines (Table 1 and see Table S1) were then validated
by testing whether independent enhancer P lines or
transgenes could also enhance the ey.RasACT pheno-
type. The interactors were also analyzed for whether they
resulted in hyperplasia alone by crossing to ey-GAL4.
Those that were unable to be confirmed by independent
enhancer P lines or transgenes, or produced only mild
enhancement with an independent line, were not pur-
sued (see Table S1). A possible reason why some of
these could not be validated by an independent trans-
gene or enhancer P line is that the GS line was inserted
in the open reading frame of the gene, and therefore
a truncated neomorphic protein may be produced (see
Table S1). Alternatively, the level of expression of the
gene may be critical for cooperation with RasACT and
the GS line may express the protein at a different level
than the independent lines. An example of this is Src,
which has previously been described as promoting hy-
perplasia at a lower level of expression, but inducing
cell death and tissue ablation when expressed at a
higher level (Vidal et al. 2007).
One validated enhancer was Delta, which is a ligand
for Notch; however, as has been previously described
(Baonza and Freeman 2005; Ferres-Marco et al. 2006),
it also showed a hyperplastic eye phenotype when ex-
pressed alone (data not shown) and was not further
analyzed. Validated enhancers exhibited phenotypes
ranging from eyes with regions of aberrant differentia-
tion (cuticle and bristles within the eye field), morpho-
logical defects, and male lethality at the pupal stage to
enlarged, overgrown adult eyes (Table 1 and Figure 2).
Strikingly, the majority of the cooperating proteins fell
into the category of Rho-family GTPases, Rho1 and
Rac1 (Settleman 2001), and Rho1 regulators, Rho-
GEF2 (Barrett et al. 1997; Hacker and Perrimon
1998) and Pbl (Prokopenko et al. 1999) (see below).
The other two cooperating proteins were the BTB/POZ
Figure 1.—- Strategy for RasACT-cooperating
gene screen: scanning electron micrographs of
adult eyes (dorsal and lateral views) from female
or males flies expressing oncogenic Ras (RasACT )
and activated aPKC (aPKCDN) or knockdown of
Dlg (dlgRNAi), compared with RasACT alone and
controls. Posterior is to the left and dorsal is to
the top in the lateral views, in this and all other
adult eye figures. (A) ey-GAL4 UAS-GFP (ey.GFP),
(B) ey-GAL4 UAS-RasACT (ey.RasACT), (C) ey-GAL4
UAS-dlgRNAi (ey.dlgRNAi), (D) ey-GAL4 UAS-RasACT
UAS-dlgRNAi (ey.RasACT dlgRNAi), (E) ey-GAL4 UAS-
aPKCDN (ey.aPKCDN), (F) ey-GAL4 UAS-RasACT
aPKCDN (ey.RasACT aPKCDN). RasACT expression
via the ey-GAL4 driver results in hyperplastic eyes.
Expression of aPKCDN or dlgRNAi via ey-GAL4
results in slight roughening. Expression of
aPKCDN or dlgRNAi with RasACT via ey-GAL4 results
in enhanced overgrowth of the RasACT hyperplas-
tic adult eye. Males expressing RasACT and
aPKCDN die at the pupal stage. (G) Diagram of
ey.RasACT screening strategy. ey-GAL4 UAS-RasACT
flies were crossed to a library of enhancer P (GS)
lines, expressing via UAS(GAL4) adjacent genes
(UAS-gene “X” ), and those which enhanced the
ey.RasACT phenotype were selected for further
analysis.
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and Psq domain nuclear localized protein, Ribbon
(Rib), required for cell shape changes and epithelial
morphogenesis (Bradley and Andrew 2001; Shim
et al. 2001), and the nuclear cytoskeletal regulator, East
(Wasser and Chia 2000) (Figure 2, see Figure S1, and
Figure S2).
The effects of the RasACT-cooperating genes on cell
survival, proliferation, differentiation, and morphol-
ogy: Expression of the RasACT-cooperating genes alone
did not result in hyperplasia, and indeed rib, Rho1, and
RhoGEF2 resulted in small eyes with morphological
defects, suggesting that they were inducing cell death
(see Figure S1 and Figure S2). Since activation of Ras
inhibits apoptosis (Bergmann et al. 1998; Kurada and
White 1998), it was possible that RasACT was cooperat-
ing with these genes by preventing cell death. However,
expression of the cell-death inhibitor, P35 (a caspase
inhibitor, Hay et al. 1994), with the RasACT-cooperating
genes did not lead to increased hyperplasia (see Figure
S1 and Figure S2), although the male lethality of Rho1
was rescued by expressing p35 (see Figure S2). Thus,
RasACT does not cooperate by simply blocking cell
death, although it is possible that its cell survival func-
tion could contribute to the cooperative effects. There-
fore, RasACT must be providing other functions, such as
promoting cell growth and proliferation or affecting
cell–cell adhesion, as has been previously reported
(Prober and Edgar 2000; Prober and Edgar 2002;
O’keefe et al. 2007), and we have observed in coopera-
tive tumorigenesis with scrib mutants (Brumby and
Richardson 2003).
As detailed below, while all of the RasACT-cooperating
genes enhanced RasACT tissue growth, a spectrum of
cooperative effects were observed: pbl, Rac1, and east
enhanced RasACT tissue growth, RhoGEF2 enhanced
the effect of RasACT on tissue growth, as well as affected
cell morphology and differentiation, and Rho1 or rib
(which alone had strong morphology defects, differ-
entiation defects, and disorganized proliferation pat-
terns) cooperated with RasACT by enhancing tissue
growth, as well as affecting cell morphology and differ-
entiation (see Figure S1, Figure S2, Figure S3, and Fig-
ure S4).
Rac1: The GS line and an independent transgene for
Rac1 (Luo et al. 1994) showed similar hyperplastic phe-
notypes with RasACT (Figure 2, C and D). In the larval
eye disc, expression of Rac1 alone did not affect eye
development; however, with RasACT it resulted in an in-
creased tissue growth and morphological defects, al-
though differentiation still occurred, albeit aberrantly
patterned (see Figures S3 and Figure S4).
Rho1: The Rho1 GS line showed a strong effect with
ey.RasACT resulting in male lethality (Figure 2E); how-
ever, expression of several Rho1 transgenes did not en-
hance the ey.RasACT phenotype to the same extent as
the GS line, although UAS-Rho1CFP2a (Greco et al. 2001)
showed slight to moderately increased hyperplasia (see
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Figure 2.—- Interaction of cooperating GS lines with ey.RasACT and validation: scanning electron micrographs of adult eyes (dorsal
and lateral views) from female or male flies expressing RasACT and cooperating GS lines or UAS transgenes via the ey driver, compared
with ey.RasACT alone and wild-type control eyes. (A) Control (w1118), (B) ey.RasACT, (C) ey.RasACT GS13019 (Rac1), (D) ey.RasACT
Rac1, (E) ey.RasACT GS12503 (Rho1), (F) ey.RasACT Rho1ACT, (G) ey.RasACT GS45 (RhoGEF2), (H) ey.RasACT RhoGEF2, (I) ey.RasACT
GS14458 (pbl), (J) ey.RasACT pblGFP#8, (K) ey.RasACT GS9641 (rib), (L) ey.RasACT GS1211 (east), (M) ey.RasACT east. Expression of
ey.RasACT with GS9641 (rib), GS12503 (Rho1), or RhoGEF2 was male lethal, and with rib was male and female lethal.
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Figure S2). Expression of the Rho1 GS line alone via
the ey driver led to male lethality and females had
very reduced eyes with differentiation defects, but
ey.Rho1CFP2a did not noticeably affect the adult eye
(see Figure S2). It is possible that the wild-type Rho1
transgenes tested did not express Rho1 to the same le-
vel as the GS line, and therefore could not accumulate
sufficient levels of active GTP-bound Rho to show co-
operation with RasACT. Therefore, we tested an acti-
vated allele of Rho1, Rho1V14 (Rho1ACT) (Lee et al.
2000). Rho1ACT alone was male lethal, but female eyes
were not as severely affected as with Rho1GS12503 (see
Figure S2). Expression of Rho1ACT with RasACT strongly
enhanced the ey.RasACT phenotype (Figure 2F, and see
Figure S2), indicating that activated Rho was required
for cooperation with RasACT. Consistent with the effect
on the adult eyes, Rho1 or Rho1ACT alone resulted in
very small eye discs, although S phases were observed
throughout the eye disc, and exhibited altered cell
morphology and reduced differentiation (see Figure
S3 and Figure S4). Coexpression of RasACT with Rho1
or Rho1ACT resulted in larger eye discs relative to
these genes alone; however, proliferation and differ-
entiation were similarly affected (see Figure S3 and
Figure S4).
RhoGEF2: The GS line targeting RhoGEF2 and an in-
dependent RhoGEF2 transgene (Mulinari et al. 2008)
cooperated with ey.RasACT (Figure 2, G and H, and see
Figure S2). However, the RhoGEF2 transgene showed
more severe effects than the GS line, resulting in
greater hyperplasia in females and male lethality at the
pupal stage (Figure 2H; see Figure S2; and data not
shown). When expressed alone the RhoGEF2 transgene
was also more severe than the GS line, resulting in ab-
lation of eye tissue (Figure S2). Consistent with these
effects on the adult eye, in the larval eye discs, RhoGEF2
alone resulted in aberrant proliferation patterns, tissue
morphology (see Figure S3), and partially blocked dif-
ferentiation (see Figure S4), and when expressed with
RasACT they strongly affected tissue morphology and
blocked differentiation (see Figure S4).
Pbl: GS lines targeting pbl, and two out of five inde-
pendent pbl transgenes (Somers and Saint 2003), en-
hanced the ey.RasACT phenotype (Figure 2, I and J, and
see Figure S2; and data not shown). Of the independent
transgenes, UAS-pblGFP#8 showed a stronger effect than
UAS-pblGFP#3 (data not shown). Although we have not
tested it directly, it is possible that the level of pbl ex-
pression is critical for the cooperative effects with
RasACT. In the larval eye disc, expression of pbl alone
did not prevent differentiation nor did it substantially
affect the pattern of S phases or tissue morphology (see
Figure S3 and Figure S4). Coexpression of RasACT with
pbl resulted in an enhancement of the tissue growth
effect of RasACT, as well as morphological defects,
although differentiation still occurred, albeit in an ab-
errant pattern (see Figure S3 and Figure S4).
Rib: An independent transgene of rib (Bradley and
Andrew 2001) resulted in a more extreme phenotype
than the GS line with ey.RasACT, since it was lethal in
both males and females (data not shown). Expression
of rib GS line alone via the ey driver resulted in reduced
adult eyes with differentiation defects in both males and
females (see Figure S1), while the rib transgene was
male and female lethal when expressed with ey-GAL4.
Consistent with the adult phenotypes, expression of rib
alone resulted in very small eye discs, although S phases
were observed throughout the eye disc, that had altered
cell morphology and reduced differentiation (see Fig-
ure S3 and Figure S4). Coexpression of RasACT with rib
resulted in larger eye discs relative to rib expression
alone; however, proliferation and differentiation were
similarly affected (see Figure S3 and Figure S4).
East: The cooperation of east with RasACT was con-
firmed by expression of a UAS-east transgene (Wasser
and Chia 2000) (Figure 2, L and M). In larval eye discs,
expression of east alone did not prevent differentiation
(see Figure S4) or obviously affect the pattern of S
phases or tissue morphology (see Figure S3), but with
RasACT it enhanced the tissue growth effect of RasACT
and led to morphological and differentiation defects
(see Figure S3 and Figure S4).
The requirement of Rac or Rho1 activity for co-
operation with RasACT: Since Pbl and RhoGEF2 are
known actin cytoskeletal regulators that function
through the Rho-family GTPase, Rho1 (Hacker and
Perrimon 1998; O’keefe et al. 2001; Padash Barmchi
et al. 2005; Patch et al. 2009), we reasoned that other
RasACT-cooperating genes may work in a common path-
way via Rho1 or Rac1 in their cooperation with RasACT.
To address this, we assessed the requirement of Rho1 or
Rac1 on the ability of the RasACT-cooperating genes for
the cooperation with RasACT in a whole-tissue setting.
To block Rac1 function we expressed a dominant neg-
ative allele, blocked in the inactive GDP-bound state,
Rac1N17 (Rac1DN) (Luo et al. 1994). Three Rac genes
in Drosophila have overlapping functions and it is likely
that the Rac1 dominant-negative allele interferes with
the function of all Rac genes (Hakeda-Suzuki et al.
2002). To reduce Rho1 function, we used a RNAi trans-
gene (Rho1RNAi), which has been shown to effectively
knockdown Rho1 protein levels and function (Massarwa
et al. 2009; Yan et al. 2009). While expression of Rac1DN
or Rho1RNAi showed no discernable effects alone (data
not shown) or on the ey.RasACT phenotype (see Figure S5),
Rac1DN suppressed the cooperation with Rac1 and RasACT,
and Rho1RNAi suppressed Rho1GS12503 and Rho1ACT co-
operation with RasACT, as expected (Table 2; see Figure
S6). Both Rac1DN and Rho1RNAi showed suppression of
the ey.RasACT dlgRNAi and ey.RasACT aPKCDN phenotypes
(Table 2; see Figure S5). RhoRNAi suppressed RhoGEF2
and pbl cooperation with RasACT (Table 2; see Figure
S7), as expected. Interestingly, Rac1DN suppressed pbl and
showed partial suppression of RhoGEF2 cooperation
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with ey.RasACT, but did not alter the ability of
Rho1GS12503, Rho1ACT, rib, or east to cooperate with
RasACT (Table 2; see Figure S6 and Figure S7). RhoRNAi
partially suppressed ribGS9641 (although not the stronger
rib transgene; data not shown), but not Rac1 or east
(Table 2; see Figure S6 and Figure S7). Collectively,
these genetic interactions are consistent with the no-
tion that Dlg, aPKC, RhoGEF2, and Pbl act upstream
of Rho1 and Rac in their cooperative effects with
RasACT. These results also suggest that in their coopera-
tion with RasACT, Rib acts upstream of Rho1 and East
acts downstream or independently of Rho1 and Rac.
The requirement of aPKC activity for the coopera-
tion with RasACT: Since we have previously shown that
the scrib mutant clonal phenotype depends on aPKC
and that aPKC contributes to the cooperative tumori-
genesis of scrib mutants with RasACT or NotchACT (Leong
et al. 2009), we tested whether the RasACT-cooperating
genes also required aPKC for their cooperative effects.
We blocked aPKC activity by expression of a kinase-dead
(dominant-negative) transgene (aPKCDN )(Sotillos et al.
2004), which in clones can suppress the defects of scrib
or lgl mutants (Grzeschik et al. 2007; Leong et al.
2009). aPKCDN exhibited no effect upon the ey.RasACT
phenotype (see Figure S5); however, it partially sup-
pressed the cooperative effect of dlgRNAi with RasACT
(Table 2 and see Figure S5), consistent with the antag-
onistic relationship between these proteins (as de-
scribed previously). Surprisingly, aPKCDN did not
suppress the ey.RasACT aPKCDN phenotype (Table 2
and see Figure S5), perhaps due to high expression of
aPKCDN, although it can suppress weaker activated
aPKC phenotypes due to expression of a membrane-
tethered aPKC construct (aPKCCAAX-WT; Sotillos
et al. 2004 and data not shown). aPKCDN was unable
to suppress the cooperative effects of any of the other
RasACT-cooperating genes (Table 2, see Figure S6 and
Figure S7), suggesting that aPKC acts upstream or in-
dependently of these genes.
JNK is upregulated and is required for the cooper-
ative effect of Rho-GTPases and Rho-family regulators
with RasACT: Activation of JNK is critical for cooperative
tumorigenesis of scrib mutants with RasACT or NotchACT
(Leong et al. 2009). To determine the involvement of
JNK signaling in the cooperation of ey.RasACT with
RhoGEF2 and Rac1, we first tested whether JNK activity
was increased in these eye discs, using the msn-lacZ re-
porter to monitor JNK pathway activity (Mattila et al.
2005). Expression of RasACT via ey-GAL4 resulted in
a weak induction of msn-lacZ in some cells in the eye
disc (Figure 3, A and B), which was expected because of
previous findings on the regulation of Jun and Fos ac-
tivity via the Ras-MAPK signaling pathway (Kockel et al.
1997; Ciapponi et al. 2001). However, coexpression of
Rac1 or RhoGEF2 with RasACT resulted in a more consis-
tent and stronger upregulation of msn-lacZ throughout
the eye disc (Figure 3, C and D). Thus, in the ey.RasACT
system, JNK activity is induced by Rac1 or RhoGEF2
expression.
We then tested if blocking JNK signaling, by expres-
sion of kinase-dead (dominant negative) transgene
(bskDN), could affect the cooperation of the RasACT-
cooperating genes with RasACT on the adult eye pheno-
types. As expected on the basis of our findings in the
clonal setting (Leong et al. 2009), bskDN strongly sup-
pressed the cooperation of RasACT with dlgRNAi or
aPKCDN, but did not affect the ey.RasACT phenotype
(Table 2 and see Figure S5). Expression of bskDN also
suppressed the cooperation of RhoGEF2, pbl, Rac1, and
Rho1ACT and partially suppressed the stronger pheno-
type of Rho1GS12503 with RasACT (Table 2, see Figure S6,
and Figure S7). Consistent with this, expression of bskDN
resulted in a suppression of the ectopic S phases ob-
served in posterior region of ey.RasACT 1 Rac1 or Rho-
GEF2 eye discs (Figure 3, E–H). Thus, in the ey.RasACT
system, JNK activity is required for the increased pro-
liferation observed in Rac1 or RhoGEF2 1 RasACT eye
discs. However, bskDN failed to suppress the cooperative
effects of east or rib with RasACT (Table 2, see Figure S7).
Since it is conceivable that bskDN could function by act-
ing on other MAPK-family signaling pathways, such as
p38, to confirm that these interactions were due specif-
ically to blocking the JNK signaling pathway, we also
tested whether reducing the dosage of bsk would
TABLE 2
Summary of genetic interactions of Rho1, Rac1, aPKC, or bsk with ey.RasACT 1 cooperating genes
ey.RasACT ey.RasACT Rac1DN ey.RasACT Rho1RNAj ey.RasACT aPKCDN ey.RasACT bskDN
UAS-dlgRNAj Enhanced Slight suppression Slight suppression Slight suppression Suppression
UAS-aPKCDN Enhanced Suppression Suppression No suppression Suppression
UAS-Rac1 Enhanced Suppression No suppression No suppression Suppression
GS12503(Rho1) Enhanced No suppression Suppression No suppression Slight suppression
UAS-Rho1ACT Enhanced No suppression Suppression No suppression Suppression
UAS-RhoGEF2 Enhanced Slight suppression Suppression No suppression Suppression
UAS-pblGEF#8 Enhanced Slight suppression Slight suppression No suppression Suppression
GS9641(rib) Enhanced No suppression Slight suppression No suppression No suppression
UAS-rib Enhanced No suppression No suppression No suppression No suppression
UAS-east Enhanced No suppression No suppression No suppression No suppression
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suppress the ey.RasACT1 RhoGEF2 or Rac1 phenotypes.
Indeed, bsk2/1 suppressed the cooperative overgrowth
phenotypes of Rac1 or RhoGEF2 with RasACT (see Figure
S8). Collectively, these data suggest that RhoGEF2, pbl,
Rac1, and Rho1 require JNK activity for their coopera-
tion with RasACT, but that east and rib cooperate with
RasACT independently of JNK.
Finally, to determine whether upregulation of JNK
signaling was sufficient for cooperation with RasACT, we
coexpressed RasACT (via the ey driver) with various trans-
genes encoding components of the JNK signaling path-
way (Stronach 2005); Bsk ( JNK), Hep ( JNK kinase),
HepACT (activated version of Hep), Msn ( JNK kinase
kinase kinase), and Eiger (tumor necrosis factor, TNF,
homolog, which signals through the JNK pathway). We
also knocked down a negative regulator of the pathway,
the JNK phosphatase, Puc (using UAS-pucRNAi), in the
ey.RasACT background. Expression of these transgenes
or RNAi had no discernable effect when expressed
alone (data not shown) and did not enhance the
ey.RasACT phenotype (see Figure S8 and data not
shown). Thus, JNK signaling is required, but is not suf-
ficient, for the cooperation with RasACT in the whole eye
tissue setting.
In a clonal setting, Rac1, Rho1ACT, RhoGEF2, and pbl
cooperate with RasACT in tumorigenesis: Mutations in
genes, such as scrib, that affect cell morphology, result in
tumors when the whole tissue is mutant, but are unable
to do so when mutant cells are generated in clones sur-
rounded by wild-type tissue (Brumby and Richardson
2003; Pagliarini and Xu 2003). This phenomenon is
due to induction of cell-competitive mechanisms lead-
ing to JNK-mediated cell death (Adachi-Yamada and
O’connor 2004; Igaki 2009; Johnston 2009). However,
while RasACT itself in clones results in some hyperplasia
and ectopic differentiation in the eye field relative to
wild type (Figure 4, A–D), when it is expressed in scrib-
clones in the eye disc, mutant clones outgrow the wild-
type tissue forming massive neoplastic tumors that invade
between the brain lobes (Brumby and Richardson
2003; Pagliarini and Xu 2003; Leong et al. 2009). On
the basis of these findings, we wished to test whether the
Figure 3.—- The JNK pathway is
upregulated in ey.RasACT 1 Rac1 or
ey.RasACT 1 RhoGEF2, and blocking
JNK reduces the overgrowth by decreas-
ing the number of S phases: (A–D) LacZ
staining of eye discs from female larvae
of: (A) ey-GAL4 msn-lacZ, (B) ey.RasACT
msn-lacZ, (C) ey.RasACT Rac1 msn-lacZ,
(D) ey.RasACT RhoGEF2 msn-lacZ. Rac1
or RhoGEF2-expressing eye discs show
increased LacZ staining (msn expres-
sion). (E–H) BrdU labeling of eye discs
from: (E) ey.RasACT Rac1, (F) ey.RasACT
Rac1 bskDN, (G) ey.RasACT RhoGEF2, (H)
ey.RasACT RhoGEF2 bskDN. The ectopic S
phases are suppressed by blocking JNK
signaling with bskDN. In E, the arrowhead
marks the second mitotic wave. Scale
bars, 50 mm.
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ey.RasACT cooperating genes could cooperate with
RasACT in a clonal setting.
Rac1: When expressed alone, Rac1 showed many
small clones that were basally excluded with pyknotic
features, suggesting that cells were dying or being out-
competed (see Figure S9). Rac1 cooperated with RasACT
to form large neoplastic tumors, particularly in the basal
sections, and differentiation was largely blocked (Figure
4, E and F). Larvae harboring these tumors showed an
extended larval lifetime, over which the tumors contin-
ued to grow, reaching massive sizes, similar to scrib- 1
RasACT tumors (see Figure S10).
Rho1: Rho1GS12503 expression resulted in very small
clones, suggesting that they were dying or being out-
competed; however, coexpression of RasACT with
Rho1GS12503 did not improve clonal survival (see Figure
S11). Since activated Rho1 (Rho1ACT ) was able to co-
operate better than wild-type Rho1 when expressed in
the whole eye tissue (Figure 2, D and E), we envisaged
that Rho1ACT may be able to cooperate with RasACT in
clones. Indeed, while Rho1ACT alone resulted in small
clones and morphological defects, Rho1ACT 1 RasACT
tumors showed overgrowth during the extended larval
lifetime forming invasive tumors, as scored by invasion
between the brain lobes (see Figure S12).
RhoGEF2: Expression of RhoGEF2 alone resulted in
small clones exhibiting features of dying cells (see Fig-
ure S9). RhoGEF2 cooperated with RasACT to form large
neoplastic tumors, particularly in the basal sections,
with reduced differentiation (Figure 4, G–H), and the
tumors increased in size over the extended larval life
span, although were not as large as scrib-1 RasACT tumors
(see Figure S10).
Pbl: Expression of pbl alone produced wild-type
sized clones, although some basally extruded differ-
entiated cells were observed (see Figure S9). Similar
to RhoGEF2 1 RasACT, pbl cooperated with RasACT to
form large neoplastic tumors, with reduced differentiation
(Figure 4, I–J) and showed massive overgrowth over the
extended larval stage (see Figure S10).
Rib: rib expression via the transgene of GS line re-
sulted in very small clones, suggesting that they were
dying or being outcompeted (see Figure S11; data not
shown). Coexpression of RasACT with ribmildly increased
rib clonal size, but did not lead to tumor formation (see
Figure 4.—- Analysis of the cooperation of Rac1, RhoGEF2,
and pbl with RasACT in eye disc clones: expression of RasACT
with cooperating oncogenes in clones compared with controls
from day 5 staged larvae stained for F-actin and ELAV. Clones
are positively marked by GFP. (A) FRT82B control, apical sec-
tion; (B) FRT82B control, basal section; (C) RasACT clones,
apical section; (D) RasACT clones, basal section; (E) RasACT 1
Rac1, apical section; (F) RasACT 1 Rac1, basal section; (G)
RasACT1 RhoGEF2, apical section; (H) RasACT1 RhoGEF2, basal
section; (I) RasACT 1 pblGFP#3, apical section; (J) RasACT 1
pblGFP#3, basal section. In C, the arrowhead points to a patch
of ectopic differentiation. Expression of Rac1, RhoGEF2, or
pblGFP#3 with RasACT results in large overgrowths, more promi-
nently in basal sections. Non-cell-autonomous overgrowth is
also observed around the clones as evidenced by tissue folding
seen by F-actin staining. Scale bars, 50 mm.
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Figure S11). Interestingly, rib1 RasACT eye discs showed
non-cell-autonomous overgrowth effects, suggesting
that RasACT may impart “un-dead” cell characteristics
to the rib-expressing cells, allowing the release of morph-
ogens that promote compensatory proliferation of the
surrounding wild-type tissue, as has been previously de-
scribed (reviewed by Fan and Bergmann 2008).
East: east-expressing clones alone in the eye disc did
not appear to show any morphological or differentia-
tion abnormities and coexpression of east with RasACT
resulted in a similar phenotype to RasACT alone (see
Figure S11). Thus, unlike the situation in the whole
eye disc, East did not cooperate with RasACT to promote
hyperplasia or neoplasia in the clonal system.
Taken together, these data show that Rac1, an acti-
vated allele of Rho1 (Rho1ACT ), RhoGEF2, and pbl, but
not Rho1, rib, or east, were capable of cooperating with
RasACT in a clonal setting. The differences observed be-
tween cooperative effects of these genes in the whole tis-
sue vs. the clonal setting highlight the context dependent
nature of RasACT-mediated cooperative tumorigenesis.
JNK is upregulated in eye disc clones of RasACT 1
Rac1 or RhoGEF2, and is required and sufficient for
cooperative neoplastic overgrowth: We then tested
whether the JNK pathway was upregulated in eye disc
clones upon the expression of Rac1 or RhoGEF2 with
RasACT by monitoring the expression JNK pathway re-
porter, msn-lacZ. In RasACT 1 Rac1 or RhoGEF2 1
RasACT-expressing clones, in either apical or basal sec-
tions, high levels of JNK signaling were observed (Fig-
ure 5, B, C, F, G) compared with RasACT-expressing
clones alone (Figure 5A) or wild-type discs (see Figure
3A). Indeed, in RasACT 1 Rac1-expressing clones, high
levels of msn-lacZ expression were also observed in the
tissue invading between the brain lobes (Figure 5D),
consistent with a role for JNK in promoting cell migra-
tion and invasion. The increased expression of msn-lacZ
in the RhoGEF2 1 RasACT-expressing clones (Figure 5,
F and G), compared with RasACT clones alone, likely
reflected increased levels of JNK activation due to
RhoGEF2 activity, since expression of RhoGEF2 alone
in clones also exhibited an upregulation of msn-lacZ
expression (Figure 5E). This is likely to also be the case
for Rac1, although we were unable to analyze the ex-
pression of msn-lacZ in clones expressing Rac1 alone,
since in this genetic background the clones were poorly
viable (data not shown).
To determine the importance of JNK on the co-
operative overgrowth in the clonal setting, we blocked
the JNK pathway, using bskDN, in Rac1 1 RasACT or
RhoGEF2 1 RasACT-expressing clones (Figure 6). Indeed,
expression of bskDN increased differentiation and restored
pupation of both Rac1 1 RasACT (Figure 6, C and D
compared with Figure 6, A and B) and RhoGEF21 RasACT
(Figure 6, G and H, compared with Figure 6, E and F)-
expressing clones. Furthermore, bskDN reduced the in-
vasive cell morphology of Rac1 1 RasACT-expressing
clones and decreased the invasive properties of the tu-
mor (Figure 6, C and D, compared with Figure 6, A
and B and data not shown). Furthermore, the expres-
sion of bskDN in Rho1ACT1 RasACT-expressing clones also
restored pupation, increased differentiation, and pre-
vented invasion between the brain lobes (see Figure
S13). Collectively, these data show that the activation
of JNK is essential to preventing differentiation,
for blocking pupation, and for the invasive behavior
of RhoGEF2 1 RasACT, Rac1 1 RasACT, or Rho1ACT 1
RasACT tumors. However, at least in the case of Rac1 1
RasACT 1 bskDN the tumors were still larger than RasACT
clones alone. These data indicate that in Rac1 1 RasACT
tumors a JNK-independent signal appears to drive addi-
tional overgrowth. This is in contrast to the whole-tissue
system in which the increased proliferation of Rac1 1
RasACT eye discs was JNK dependent (Figure 3, E and
F). RhoGEF2 1 RasACT 1 bskDN or Rho1ACT 1 RasACT1
bskDN tumors were more similar to RasACT alone, so in
these cases (and possibly also Rac1 1 RasACT tumors)
a JNK-dependent signal is required for additional over-
growth. The requirement for JNK in this additional
overgrowth is likely to relate to JNKs ability to block
differentiation and pupation in these RasACT-expressing
clones, thereby enabling tumor overgrowth during an
extended larval phase (see discussion).
Finally, to examine whether activation of JNK was
sufficient to cooperate with RasACT in a clonal setting,
we expressed a UAS-bsk transgene alone or in combina-
tion with UAS-RasACT in eye disc clones and analyzed
clonal growth with time (see Figure S14). Expression
of bsk alone in clones resulted in small clone size and
many cells exhibited a pyknotic phenotype, suggesting
that cells were undergoing apoptosis or being outcom-
peted (see Figure S14). By contrast, expression of
RasACT with bsk rescued the cell-death phenotype of
bsk-expressing clones and at day 5, eye discs were similar
to RasACT expression alone (see Figure S14). However,
some bsk 1 RasACT mosaic larvae exhibited an extended
larval phase in which the tumor overgrew the surround-
ing wild-type tissue (see Figure S14). The tissue over-
growth was associated with altered cell morphology and
aberrant differentiation. Moreover, in older larvae, tu-
mor invasion was observed between the brain lobes (see
Figure S14). Collectively, our data show that in a clonal
setting, activation of JNK is sufficient to block pupation,
promote RasACT–mediated proliferation, disrupt differ-
entiation, and induce invasive properties.
Cooperation of Ha-RasV12 and JNK signaling in mam-
malian breast epithelial cells and in human cancer:
Given our findings of the importance of JNK signaling
in Drosophila RasACT-mediated cooperative tumorigen-
esis with actin cytoskeletal regulators, we sought to
investigate the requirement of JNK signaling for coop-
eration with oncogenic Ras in mammalian cell models
and in human cancer. To explore the cooperation of
JNK with activated Ras, we utilized MCF10A normal
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breast epithelial cells grown in 3D matrigel cultures.
MCF10A cells form acini in matrigel; however, upon
low-level expression of activated Harvey–Ras (Ha-
RasV12) the lumens become filled with cells and with
the concomitant knockdown of cell polarity regula-
tors, such as hScrib, cells form invasive clusters
(Dow et al. 2008)—thus this system is a useful model
with which to examine cooperative tumorigenesis.
We established MCF10A cell populations overex-
pressing JNK1a1 and the JNK kinase genes, MKK4
or MKK7, with or without Ha-RasV12 and examined
their behavior in matrigel (Figure 7, A–C). MCF10A
lines expressing JNK1a1, MKK4, or MKK7 alone
were similar to controls, while low-level Ha-RasV12 ex-
pression alone showed some invasive acini. Coexpres-
sion of JNK1a1, MKK4, or MKK7 with Ha-RasV12
Figure 5.—- Rac1 or RhoGEF2 ex-
pression in clones results in upregu-
lation of the JNK pathway: LacZ
staining, to detect msn-lacZ expres-
sion, and F-actin staining of mosaic
discs expressing Rac1 or RhoGEF2
1/2 RasACT. Clones are positively
marked by GFP. (A) RasACT clones
in msn-lacZ/1 discs, (B) RasACT 1
Rac1 clones in msn-lacZ/1 discs, api-
cal view, (C) RasACT 1 Rac1 clones in
msn-lacZ/1 discs, basal view, (D)
RasACT 1 Rac1 clones in msn-lacZ/1
discs with brain lobes, showing inva-
sion of GFP1 tissue between the
brain lobes, BL, (E) RhoGEF2 clones
in msn-lacZ/1 discs, (F) RasACT 1
RhoGEF2 clones in msn-lacZ/1 discs,
apical view, (G) RasACT 1RhoGEF2
clones in msn-lacZ/1 discs, basal view.
In D, the arrowhead points to GFP1
tissue invading between the brain
lobes. RasACT results in mild ectopic
msn-lacZ expression. RasACT1RhoGEF2
and RasACT 1 Rac1 clones show ex-
tensive upregulation of msn-lacZ. In
some RhoGEF2-expressing clones,
high levels of msn-lacZ expression
is observed. Scale bars, A–C, E–G,
50 mm; D, 200 mm.
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resulted in a 4-fold, 3-fold and 2.5-fold increase
in invasive acini relative to Ha-RasV12 alone, respec-
tively. Thus, similar to Drosophila, upregulation of
JNK in mammalian epithelial cells cooperates with
RasV12 to promote invasive properties upon normal
human epithelial cells.
We also examined the effect of expressing JNK1a1,
MKK4, or MKK7 in MCF10A cells on anchorage-
Figure 6.—- JNK signaling is required for
cooperation of Rac1 or RhoGEF2 with RasACT
in clones: clones expressing RasACT with
Rac1 or RhoGEF21/2 bskDN at day 5, stained
for F-actin and ELAV. Clones are positively
marked by GFP. (A) RasACT 1 Rac1 clones,
apical view; (B) RasACT 1 Rac1 clones, basal
view; (C) RasACT 1 Rac1 1 bskDN clones, api-
cal view; (D) RasACT 1 Rac1 1 bskDN clones,
basal view; (E) RasACT1 RhoGEF2 clones, api-
cal view; (F) RasACT 1 RhoGEF2 clones, basal
view; (G) RasACT 1 RhoGEF2 1 bskDN clones,
apical view; (H) RasACT 1 RhoGEF2 1 bskDN
clones, basal view. In B, the arrowhead points
to tissue with an invasive morphology. Expres-
sion of bskDN rescues the cooperation of Rac1
or RhoGEF2 with RasACT by increasing differ-
entiation and reducing the invasive phenotype
of Rac1 1 RasACT clones. Scale bars, 50 mm.
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independent growth (growth in soft agar; see Figure
S15). Expression of these genes alone could not con-
fer anchorage-independent growth to MCF10A cells
or modify the ability of Ha-RasV12 to promote growth
in soft agar. In 2D cultures, expression of JNK1a1,
MKK4, or MKK7 also did not enhance the proliferation
rate alone or in combination with Ha-RasV12, and indeed
MKK4 resulted in a decreased proliferation rate of Ha-
RasV12-expressing cells (see Figure S15). These data in-
dicate that upregulation of JNK signaling cooperates with
RasV12 in 3D cultures to promote invasion, but does not
enhance cell proliferation rates in 2D cultures or pro-
mote anchorage independent growth.
To further examine the relevance of our findings to
human cancer, we investigated a gene signature related
to JNK signaling (Han et al. 2002) for its association with
gene expression in breast cancer using publicly avail-
able data sets (see File S1). Breast cancers are now
divided into three major molecular subtypes, according
to estrogen receptor and HER2 expression, for clinical
and research purposes (Sorlie et al. 2001; Sorlie et al.
2003; Sotiriou et al. 2003), which are recognized to have
different biological mechanisms of tumor growth and
progression. We found that in the breast cancer subtype
that overexpresses the human epidermal growth factor
receptor (HER21), there was a moderate and positive
correlation with the JNK signature relative to the other
breast cancer subtypes (HER21 Spearman’s r ¼ 0.15, P
, 0.001; ER1/HER22 r ¼ 0.05, P ¼ 0.05; ER2/HER22
r ¼ 0.02, P ¼ 0.6; Figure 7D). As HER2 upregulation is
known to activate Ras/Erk signaling (P , 0.0001; Figure
7E), this observation is in agreement with our data, high-
lighting cooperation between Ras and JNK signaling.
The association of a high JNK signature in ER1/HER22
(“luminal” subtype) breast cancers is also consistent with
reports from previous clinical studies and xenograft
models of tamoxifen resistance, which have reported
a positive association with activated/phosphorylated
JNK ( Johnston et al. 1999; Schiff et al. 2000), although
these tumors do not show high expression of the Ras
signature (Figure 7E). While Ras is not an established
oncogene in breast cancer, Ras pathway upregulation is
recognized to be important for breast cancer growth and
tumorigenesis (reviewed by Whyte et al. 2009), and our
data support a link between Ras and JNK signaling in
HER21 breast cancers. Together these data support fur-
ther investigation into the relationship between JNK and
Ras signaling in human cancers.
DISCUSSION
In a genome-wide overexpression screen for RasACT-
cooperating genes in the developing eye, we have iden-
tified Rac1, Rho1, RhoGEF2, pbl, rib, and east, which all
have roles in regulation of cell morphology. We showed
that in a clonal setting, which reveals the competitive
ability of mutant tissue, that Rac1, an activated allele of
Rho1 (Rho1ACT ), RhoGEF2, and pbl exhibit cooperativity
with RasACT. Our studies reveal that JNK signaling is
required for the cooperation of these genes with
RasACT; however, the role of JNK is gene and context
dependent. In a whole-tissue setting, we show that (1)
expression of Rac11 RasACT or RhoGEF21 RasACT leads
to upregulation of the JNK-Jun/Fos (AP-1) target gene,
msn, (2) that JNK signaling is required for the increased
proliferative potential of Rac1 or RhoGEF2 with RasACT,
and (3) that the eye phenotypes of Rac1, Rho1 RhoGEF2,
and pbl require JNK, but (4) JNK is not sufficient for
cooperation. By contrast in a clonal setting, upregula-
tion of JNK is both necessary and sufficient for cooper-
ative tumorigenesis of Rac1, Rho1ACT, or RhoGEF2 with
RasACT: (1) JNK is upregulated in Rac1 1 RasACT or
RhoGEF2 1/2 RasACT clones, (2) blocking JNK reduces
the tumorigenic potential of Rac1, RhoGEF2, or Rho1ACT
with RasACT, and (3) upregulation of JNK alone coop-
erates with RasACT, although was less aggressive than
scrib-, Rac1, Rho1ACT, RhoGEF2, or pbl with RasACT. This
role for JNK is conserved in mammalian cells, since JNK
upregulation cooperates with activated Ha-Ras to pro-
mote invasive growth of MCF10A normal breast epithe-
lial cells in 3D cultures, and upregulation of the JNK
signature correlates with HER21 human breast cancers,
where Ras signaling is upregulated. However, upregula-
tion of JNK signaling in mammalian cells did not in-
crease the proliferation or anchorage-independent
growth properties of Ha-RasV12, consistent with our
analysis that JNK was not sufficient to promote hyper-
proliferation in the ey.RasACT system. Collectively, our
data reveal the importance of the RhoGEF/Rho-family/
JNK pathway for cooperative tumorigenesis with RasACT.
Moreover, our data reveal that the cooperation of JNK
with oncogenic Ras in tumorigenesis is conserved be-
tween Drosophila and humans and highlights the rele-
vance of Drosophila screens and genetic
analysis to human cancer biology.
Context dependent effects of JNK activation on
cell behavior: Our analysis revealed that the RasACT-
cooperating genes resulted in different effects in differ-
ent contexts; when expressed alone within the whole
eye tissue the spectrum of phenotypes ranged from lit-
tle effect (Rac1, pbl, east) to reduced eyes with morpho-
logical and differentiation defects (Rho1, Rho1ACT,
RhoGEF2, rib), and with RasACT from increased hyper-
plasia (Rac1, pbl, east) or more severe morphological
and differentiation defects (Rho1, Rho1ACT, RhoGEF2,
rib), while in the clonal setting expression of the
RasACT-cooperating genes alone ranged from little ef-
fect (pbl, east) to small clones with evidence of apoptosis
(Rac1, Rho1, Rho1ACT, RhoGEF2, rib), and with RasACT
either did not cooperate (Rho1, rib and east) or resulted
in neoplastic invasive tumors (Rac1, Rho1ACT, RhoGEF2,
pbl). We hypothesize that these spectrums of pheno-
typic outcomes are related to the severity of cell-
morphology disruption and to different levels of Rho1
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Figure 7.—- Cooperation of JNK and Ras signaling in normal mammalian epithelial cells and human cancer: (A–C) JNK1a1,
MKK4, and MKK7 cooperate with Ha-RasV12 in promoting invasion of MCF10A cells in 3D matrigel cultures. A representative of
three independent experiments with three independently derived MCF10A cell line sets overexpressing JNK1a1 (A),MKK4 (B), or
MKK7 (C) in the context of Ha-RasV12 expression is shown. Bright-field images of acini morphology (left) (scale bar, 100 mm).
Invasive morphology quantitation expressed relative to Ha-RasV12 control [*P , 0.05; Student’s t-test, two tailed, unpaired; error
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and JNK signaling, although we have not been able to
measure this directly due to the absence of reliable
Drosophila reagents for Western analysis.
The reduced eye phenotype of Rho1, Rho1ACT, RhoGEF2,
and rib when expressed alone in the whole eye tissue, is
consistent with strong activation of JNK, since ey-driven
expression of hepACT also results in reduced eyes (data
not shown). Furthermore, in cooperation with RasACT
in the whole eye disc, Rac1, Rho1, Rho1ACT, RhoGEF2,
and pbl required JNK. Indeed, Rac1 1 RasACT and
RhoGEF2 1 RasACT eye discs upregulated Jun/Fos
(AP-1) activity and JNK was required for the increased
numbers of S phase cells in these discs. Thus, RhoGEF2
and Rac1 require the activation of JNK to cooperate
with RasACT to result in increased hyperplasia. A
role for JNK in promoting proliferation has recently
been revealed in tissue regeneration after wounding
(Bergantinos et al. 2010), and the SWH tissue growth
control pathway has been implicated in this process
(Grusche et al. 2011; Sun and Irvine 2011). Whether
the SWH pathway is also required for cooperation of
JNK with RasACT to increase hyperplasia remains to be
determined.
In the clonal setting the cooperation of Rac1, Rho1ACT,
RhoGEF2, and pbl, but not Rho1, rib or east, with RasACT
could be related to their ability to upregulate JNK to
an appropriate level. Indeed the degree of overgrowth
and invasive properties may be related to the level of
JNK upregulation; Rac1 1 RasACT and scrib2 1 RasACT
tumors show a more consistent upregulation of JNK
(revealed by msn-lacZ expression) than in RhoGEF2 1
RasACT tumors, which correlates with the more severe
overgrowth and invasion of Rac1 1 RasACT or scrib2 1
RasACT tumors. Moreover, the expression of bsk ( jnk)
alone was sufficient to cooperate with RasACT to produce
large neoplastic tumors, consistent with the previous re-
port that upregulation of JNKK (Hep) expression can
also cooperate with RasACT (Uhlirova and Bohmann
2006). Uhlirova and Bohmann also showed that the level
of JNK pathway activation appears to be important for
this cooperation, since overexpression of an activated
version of hep (hepACT), which in contrast to bsk or hep
upregulation, promotes high levels of cell death when
expressed in clones (Brumby and Richardson 2003;
Leong et al. 2009), was unable to cooperate with RasACT
(Uhlirova and Bohmann 2006). These observations
may explain why Rho1 and rib (situations in which we
hypothesize that JNK signaling may be higher) did not
cooperate with RasACT in the clonal situation; the high
levels of cell death triggered by strong JNK activation
may not be able to be overcome by expression of
RasACT. Upregulation of the Ras–MAPK signaling path-
way blocks apoptosis via phosphorylation of the cell-
death inducer, Hid, as well as downregulation of hid
transcription (Bergmann et al. 1998; Kurada and
White 1998). When high levels of JNK activity are in-
duced, the activation of Hid or other cell death
inducers may not be able to be blocked by RasACT. By
contrast, since expression of east alone in clones did not
exhibit signs of cell death, east may be unable to induce
sufficient activation of JNK in the clonal setting to en-
able cooperation with RasACT.
In a clonal setting, we showed that JNK is required to
block differentiation and pupation and to promote the
invasive phenotypes of RhoGEF2, Rac1, and Rho1ACT
in cooperation with RasACT, although not the cell-
morphology defects. The effect of JNK on invasion has
been shown to be due to upregulation of targets impor-
tant in cell migration, such as Paxillin, and in break-
down of the extracellular matrix, such as MMP1
(Beaucher et al. 2006; Uhlirova and Bohmann
2006; Srivastava et al. 2007; Leong et al. 2009), but
how JNK blocks differentiation and pupation is cur-
rently unknown. Expression of bskDN also reduced tu-
mor overgrowth to a level commensurate with RasACT
alone for all except Rac1 1 RasACT. The reduced differ-
entiation and delayed pupation mediated by JNK most
likely contributes to the overgrowth phenotypes, since
the overgrowth manifests during the extended larval
phase. The JNK-mediated overgrowth in these tumors
may depend upon the JAK–STAT pathway, since JNK
signaling in scrib2 cells has been shown to induce
expression of the cytokine, Unpaired (Upd), which
can lead to activation of the JAK–STAT tissue growth
control signaling pathway in scrib2 cells, but also in ad-
jacent cells wild type (Wu et al. 2010). Rac1, Rho1ACT,
RhoGEF2, and pbl 1 RasACT mosaic discs exhibited some
non-cell-autonomous tissue growth, suggesting that such
a mechanism involving JAK–STAT signaling may be
occurring.
For Rac1 1 RasACT 1 bskDN the tumors were still larger
than RasACT alone, suggesting that a JNK-independent
mechanism must be triggered to drive the overgrowth
of these tumors and their competitive advantage over
the surrounding wild-type tissue. This is similar to what
occurs in scrib- 1 RasACT tumors when JNK signaling is
blocked; although the overgrowth is reduced, tumors
are still considerably larger than with RasACT alone
(Leong et al. 2009). Pertinent to this is that while acti-
vation of JNK alone can cooperate with RasACT (this
bars represent standard deviation] (right). Western blot of whole-cell lysates probed with antibodies as indicated on the right side.
a-Tubulin was used as loading control. (D, E) Box-plots representing expression of a gene signature of JNK activation and Ras
activation in human breast cancers. The relative expression of JNK signature genes (D) and Ras signature genes (E) were
compared using gene expression data and divided according to the three major molecular breast cancer subtypes: ER2/HER22
(triple negative), HER21, and ER1/HER22 (luminal). The correlation with high JNK signature expression in HER21 and ER1/
HER22 is higher than in the other breast cancer subtypes, and of these the Ras signature is higher in the HER21 subtype (P, 0.0001).
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study; Uhlirova and Bohmann 2006), the cooperative
effect is not as potent as with Rac1 1 RasACT or scrib2 1
RasACT, raising the possibility that these genes are affect-
ing other processes to mediate cooperative overgrowth.
This may include the integrity of the E-cadherin–
b-catenin complex, which has been revealed to also
contribute to RasACT-mediated cooperative tumouri-
genesis (Igaki et al. 2006). Furthermore, we and others
have recently shown that the SWH pathway, which
inhibits both cell proliferation and survival, is deregu-
lated by loss-of-function of the polarity regulator, Lgl, in
the eye disc (Grzeschik et al. 2010), and in lgl2 1
RasV12 clones in the wing disc (Menendez et al. 2010).
Therefore deregulated SWH signaling could contribute
to the increased proliferative potential of Rac11 RasACT
or scrib2 1 RasACT tumors independently of JNK. Other
factors, such as the relative level of the Myc cell growth
protein, which has been shown to affect the survival of
lgl2 clones in the wing disc (Froldi et al. 2010), or the
recently discovered membrane protein isoform, Flower-
Lose, which is associated with dying cells in cell compe-
tition (Rhiner et al. 2010), may also be involved in the
overgrowth of Rac1 1 RasACT or scrib2 1 RasACT tumors.
Hierarchical relationships between the RasACT-
cooperating genes: Our genetic analysis of the RasACT-
cooperating genes with Rho1, Rac1, aPKC, and bsk (jnk)
in the whole eye (Table 2) has revealed an interaction
relationship between these genes (Figure 8). We found
that blocking aPKC, with the kinase-dead (dominant-
negative) form, partially suppressed the dlgRNAi 1
RasACT cooperative phenotype, but not other coopera-
tive interactions, suggesting that aPKC acts downstream
of Dlg (consistent with the antagonistic relationship be-
tween basal-lateral cell polarity regulators and aPKC,
reviewed by Humbert et al. 2008). Analysis of the genetic
interactions of the RasACT-cooperating genes with JNK,
revealed that JNK acts downstream of dlgRNAi, aPKCDN,
Rac1, Rho1 (and Rho1ACT ), RhoGEF2, and pbl in cooper-
ation with RasACT (Table 2 and Figure 8). The cooper-
ation of east with RasACT was epistatic to rho1, rac1, bsk,
and aPKC, and therefore east must act downstream or
independently of these genes in its cooperation with
RasACT to result in increased hyperplasia.
Analysis of the epistatic relationships of the RasACT-
cooperating genes (Table 2) revealed that RhoGEF2 and
pbl required both Rac1 and Rho1 activity for their co-
operation with RasACT (Figure 8). The requirement for
Rho1 is consistent with previous studies (Barrett et al.
1997; Hacker and Perrimon 1998; O’keefe et al.
2001); however, the requirement of Rac1 for RhoGEF2
or Pbl function is novel and may be manifest only in the
presence of RasACT. We also found that dlgRNAi and
aPKCDN cooperation with RasACT required Rac1 and
Rho1 function (Table 2 and Figure 8); however,
whether their cooperation with RasACT requires Rho-
GEF2 or pbl remains to be determined. The mammalian
homolog of Pbl (Ect2) can bind to the aPKC (PKCz)/
Par3/Par6 complex, but Ect2 was shown to regulate
aPKC activity (Liu et al. 2004) rather than vice versa, as
we would predict.
The cooperation of rib with RasACT was not sup-
pressed by bskDN, but was suppressed by Rho1RNAi such
that the female eyes now exhibited a hyperplastic phe-
notype and male lethality was rescued (Table 2). It is
difficult to explain in relation to the model (Figure 8)
why the rib 1 RasACT phenotype was suppressed by
Rho1RNAi, but not bskDN. It is possible that JNK is upre-
gulated so highly by rib expression that it cannot be
blocked by the bskDN transgene, but the Rho1RNAi trans-
gene is more effective in downregulating Rho1. The
genetic interaction of rib 1 RasACT cooperation by
Rho1RNAi suggests that Rho1 acts downstream of Rib to
mediate cooperation with RasACT. Since Rib is a nuclear-
localized protein, thought to be a transcription factor
(Bradley and Andrew 2001; Shim et al. 2001), it is
possible that Rib may upregulate the expression of
Rho1 or Rho1 regulators to mediate its known effects
on epithelial migration and morphogenesis ( Jack and
Myette 1997; Blake et al. 1998), as well as in cooper-
ation with RasACT. Interestingly, Rib has been shown to
Figure 8.—Model of interactions of RasACT-cooperating
genes: genetic epistasis tests reveal a possible model of how
the RasACT-cooperating genes may function in a pathway to
lead to the upregulation of JNK in the ey-GAL4 system. Expres-
sion of RasACT alone via ey-GAL4 leads to hyperplasia. Pathways
shown in black lead to increased hyperplasia, while those in
red lead to differentiation defects and morphological
changes, which we propose is due to higher levels of Rho1
and JNK signaling. Proteins shown in green are hypothesized
to be required for the effects, on the basis of information in
other systems (see text). Since JNK is required, but not suffi-
cient, to cooperate with ey.RasACT, we hypothesize that other
factors (X or Y) are altered by Rho1 or Rac1 signaling to
enable cooperation with RasACT. Whether knockdown of Dlg
or activation of aPKC requires Pbl or RhoGEF2 is not known
(indicated by ?). See text for further details.
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upregulate the expression of the apical polarity regula-
tor, Crb, and downregulate Moesin (Moe) to facilitate
salivary gland and tracheal tube elongation (Kerman
et al. 2008). Since Moe is a negative regulator of Rho1
(Speck et al. 2003), upregulation of Rib would be pre-
dicted to increase Rho1 activity to mediate its affects on
cell morphology. Since Rib also upregulates crb tran-
scription (Kerman et al. 2008), and we and others have
shown that high Crb levels deregulates the SWH signal-
ing pathway to promote tissue growth (Grzeschik et al.
2010; Robinson et al. 2010), it is possible that suppres-
sion of Rho1 activity in rib 1 RasACT eye discs unleashes
this cryptic activity of Rib in tissue growth via its effect
on Crb.
Taken together, our genetic interaction data are
consistent with a model whereby RhoGEF2 and Pbl
act through Rho1 and Rac1 to activate JNK and increase
hyperplasia or promote morphological and differentia-
tion defects in a whole-tissue context. However, our
data have revealed that while JNK is required, it is not
sufficient for this cooperation with RasACT, suggesting
that Rho1 or Rac1 require another unidentified factor
(X or Y) for cooperation with RasACT to promote hyper-
plasia or morphological and differentiation defects
(Figure 8). In the case of dlgRNAi, aPKCDN, pbl, and
Rac1 this interaction results in a hyperplastic response
through JNK activation and the effector, X. By contrast,
Rho1GS12503 and Rho1ACT result in morphological and
differentiation defects via JNK activation and the
Rho1 effector Y (which may be equivalent to X), while
RhoGEF2 has intermediary effects. We propose that
stronger activation of Rho1 and therefore JNK in
Rho1-expressing eye discs leads to induction of a differ-
ent effector, Y, or to a higher induction of effector, X.
High activation of JNK could also contribute to the cell-
morphology changes and differentiation defects ob-
served for Rho1, since JNK has a well-described role in
cell-morphology changes during Drosophila development
(Martin-Blanco 1997; Harden 2002) and has been
shown to contribute to loss of apico-basal cell polarity in
wing imaginal discs in lgl mutants (Zhu et al. 2010).
Whether this hierarchical pathway linking polarity
regulators, through Rho1 and Rac1, to JNK activation
(Figure 8) occurs in a clonal setting remains to be de-
termined. JNK is activated in scrib2 clones by upregula-
tion of Eiger (Igaki et al. 2009), and the Drosophila
macrophage-like blood cells (hemocytes) are able to
recognize the mutant cells and provide the source of
Eiger (Cordero et al. 2010). However, since Rho1 and
Rac1 can activate JNK during morphogenesis in Dro-
sophila development (Settleman 2001), deregulation
of cell polarity regulators may also lead to JNK activa-
tion cell intrinsically, via activation of Rho-family regu-
lators, to contribute to RasACT-mediated tumorigenesis.
Indeed, Rho1 may directly activate JNK signaling, since
it can form a complex with Slipper (Slpr, a JNKKK) in
imaginal discs to active JNK-mediated cell death
(Neisch et al. 2010). Moreover, Rho1, via Rho kinase
(Rok) and Myosin II (Zipper), activates JNK to mediate
compensatory proliferation in imaginal discs (Warner
et al. 2010). Rac1 can also activate the JNK pathway di-
rectly in dorsal closure via Slpr (Garlena et al. 2010).
Whether the RasACT-cooperating genes lead to JNK ac-
tivation in either the whole-tissue or clonal context via
these mechanisms remains to be determined.
Cooperation of oncogenic Ras and JNK in mamma-
lian cancer: Our analysis has revealed that the impor-
tance of JNK activation for oncogenic Ras-mediated
tumorigenesis extends to mammalian cells, since upre-
gulation of JNK1a or its activators MKK4 or MKK7
cooperates with Ha-RasV12 in the MCF10A normal
breast epithelial cell line, to induce invasive growth in
3D matrigel cultures. However, upregulation of the JNK
signaling pathway did not cooperate with Ha-RasV12 to
increase anchorage-independent growth or cell prolif-
eration in culture. Thus in this context, JNK upregula-
tion is acting simply by promoting the invasive
properties of Ha-RasV12-expressing MCF10A cells.
Our previous studies have shown that in this system,
the cooperation of scrib loss-of-function with Ha-RasV12
is due to further upregulation of Ras signaling (Dow
et al. 2008). Whether this is also the case for JNK path-
way upregulation in cooperation with Ha-RasV12 will
require further analysis.
Our analysis has also revealed a correlation of the
JNK signaling signature with the HER21 breast cancer
subtype, which shows upregulation of Ras signaling.
This finding provides evidence that upregulation of
Ras with JNK may be important for the development
of certain types of human cancer. In mammalian cells
and human cancer, the role of JNK signaling is complex
and context dependent (Kennedy and Davis 2003;
Weston and Davis 2007; Whitmarsh and Davis
2007; Wagner and Nebreda 2009). However, our
experiments support previous evidence that JNK path-
way activation can cooperate with oncogenic Ras in
mammalian cell transformation (Nielsen et al. 2007;
Zhang et al. 2007; Ke et al. 2010); therefore, our analy-
sis, together with these findings, highlights the need for
further research into the association of Ras and JNK
status in cancer cell lines and the involvement of JNK
signaling in Ras-dependent tumors.
Mammalian homologs exist for Pbl (Ect2), RhoGEF2
(LARG, PDZ-RhoGEF, and p115-RhoGEF), and Rac1/
Rho1-family proteins (Table 1). Upregulation of these
proteins have been shown to induce cell transformation
and are associated with human cancer (Miki et al. 1993;
Fukuhara et al. 1999; Fukuhara et al. 2000; Fukuhara
et al. 2001; Sahai and Marshall 2002; Ridley 2004;
Gomez Del Pulgar et al. 2005; Titus et al. 2005). In-
deed, upregulation of Rho-family proteins has been
shown to cooperate with oncogenic Ras in enabling cell
transformation, by overcoming Ras-induced cellular se-
nescence due to upregulation of the cell-cycle inhibitor
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p21 (Olson et al. 1998; Coleman et al. 2004). Recently,
the Rac1 effector, Pak1, has been found to cooperate
with ErbB2–MAPK and PI3K signaling in promoting
growth factor-independent proliferation in 3D cultures
and to be associated with estrogen-receptor positive hu-
man breast cancers (Arias-Romero et al. 2010).
Whether JNK signaling is also involved in these cases
has not been investigated. Given our findings from this
study, further analysis of the association of mammalian
Ect2, RhoGEF2-related proteins, and Rac1/Rho1-family
members with JNK signaling, in Ras-dependent human
cancers, is warranted. Since the Ras signaling pathway is
upregulated in 30% of human cancers, but Ras itself is
not sufficient for tumorigenesis due to induction of
cellular senescence (Olson et al. 1998; Coleman et al.
2004; DeNicola and Tuveson 2009), our identifica-
tion of the importance of JNK for cooperation of Ras
with Rho-family regulators suggests new avenues of in-
vestigation in the understanding and treatment of Ras-
dependent cancers.
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